Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN US09062X1037 / Valor 1720684

NASDAQ (2025-04-03)
USD 130.71-0.46%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-36.7%1Y
-37.9%3Y
-56.5%5Y

Performance

25.9%1Y
32.8%3Y
43.0%5Y

Volatility

Market cap

22049 M

Market cap (USD)

Daily traded volume (Shares)

1,755,806

Daily traded volume (Shares)

1 day high/low

151.14 / 148.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

CryoPort Inc
CryoPort Inc CryoPort Inc Valor: 28284615
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-11.69%USD 5.44
Alignment Healthcare Inc
Alignment Healthcare Inc Alignment Healthcare Inc Valor: 110387702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.70%USD 18.51
TransMedics Group Inc
TransMedics Group Inc TransMedics Group Inc Valor: 47361695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.94%USD 70.96
PolyPeptide Group Ltd
PolyPeptide Group Ltd PolyPeptide Group Ltd Valor: 111076085
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.63%CHF 16.06
LifeStance Health Group Inc
LifeStance Health Group Inc LifeStance Health Group Inc Valor: 111701745
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.66%USD 6.74
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd Valor: 758744
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.88%USD 14.85
Service Corporation International
Service Corporation International Service Corporation International Valor: 969683
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.22%USD 81.38
Harrow Inc
Harrow Inc Harrow Inc Valor: 45675535
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-7.64%USD 24.06
Teleflex Inc
Teleflex Inc Teleflex Inc Valor: 976212
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 137.99
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.01%EUR 77.85